Alkem Laboratories Limited

rs,

th February, 2025 To, The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Excha

₹ 33,743 million

umbai today. Key highlights of Q3FY25 financial performance • Total Revenue from Operations was ₹ 33,743 million, with YoY growth of 1.5%. o India sales were ₹ 23,649 million, with YoY growth of 5.9%. o Intern

1.5%

25 financial performance • Total Revenue from Operations was ₹ 33,743 million, with YoY growth of 1.5%. o India sales were ₹ 23,649 million, with YoY growth of 5.9%. o International sales were ₹ 9,60

₹ 23,649 million

• Total Revenue from Operations was ₹ 33,743 million, with YoY growth of 1.5%. o India sales were ₹ 23,649 million, with YoY growth of 5.9%. o International sales were ₹ 9,605 million, with YoY de-growth of 6.2%.

5.9%

33,743 million, with YoY growth of 1.5%. o India sales were ₹ 23,649 million, with YoY growth of 5.9%. o International sales were ₹ 9,605 million, with YoY de-growth of 6.2%. • Earnings before Intere

₹ 9,605 million

f 1.5%. o India sales were ₹ 23,649 million, with YoY growth of 5.9%. o International sales were ₹ 9,605 million, with YoY de-growth of 6.2%. • Earnings before Interest, Tax, Depreciation, and Amortization (EBIT

6.2%

illion, with YoY growth of 5.9%. o International sales were ₹ 9,605 million, with YoY de-growth of 6.2%. • Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were ₹ 7,594 million, r

₹ 7,594 million

Y de-growth of 6.2%. • Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were ₹ 7,594 million, resulting in an EBITDA margin of 22.5% vs. 21.3% in Q3FY24. EBITDA increased by 7.3% YoY. • R&D

22.5%

ax, Depreciation, and Amortization (EBITDA) were ₹ 7,594 million, resulting in an EBITDA margin of 22.5% vs. 21.3% in Q3FY24. EBITDA increased by 7.3% YoY. • R&D expenses for the quarter were ₹ 1,312 m

21.3%

iation, and Amortization (EBITDA) were ₹ 7,594 million, resulting in an EBITDA margin of 22.5% vs. 21.3% in Q3FY24. EBITDA increased by 7.3% YoY. • R&D expenses for the quarter were ₹ 1,312 million, or

7.3%

₹ 7,594 million, resulting in an EBITDA margin of 22.5% vs. 21.3% in Q3FY24. EBITDA increased by 7.3% YoY. • R&D expenses for the quarter were ₹ 1,312 million, or 3.9% of total revenue from operatio

₹ 1,312 million

of 22.5% vs. 21.3% in Q3FY24. EBITDA increased by 7.3% YoY. • R&D expenses for the quarter were ₹ 1,312 million, or 3.9% of total revenue from operations, compared to ₹ 1,111 million in Q3FY24 at 3.3% of total

About Alkem

1

Investors

1

Media

1

Details of the conference call are as follows

1

Dial in Details

1

E-mail

1

About Alkem

Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a legacy of 50 years in providing high-quality medicines to patients. It is the fifth largest pharmaceutical company in the Indian market, with a dominant position in the therapy areas of anti- infectives, gastrointestinal, pain management drugs and supplements. It also has a growing portfolio of products in chronic therapies such as diabetes, neurology, cardiology, dermatology and urology. It has 19 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres across India and the US to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia, and several other Asian countries. “Inspiring Healthier Lives” is at the core of the values and culture of the organisation and reinforces its steadfast commitment to global health improvement. For more

Investors

Purvi Shah – Head of Investor Relations +91 84337 00890 purvi.shah@alkem.com +91-22-3982 9999 Ext: 9447 +91-22-3982 9999 Ext: 9672

Media

Isha Trivedi +91 98925 90003 alkemcorpcomm@alkem.com Invite for Q3 & 9MFY25 Conference Call at 4 pm IST, February 07, 2025 Mumbai, February 07, 2025: Alkem Laboratories Ltd. (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Friday, February 07, 2025, from 4:00 pm to 5:00 pm IST to discuss its Q3 and 9MFY25 financial results. The call will follow the announcement of the Company’s Q3 and 9MFY25 financial results on Friday, February 07, 2025. Alkem Laboratories Ltd. will be represented on the call by: Dr. Vikas Gupta – CEO Mr Nitin Agrawal – CFO Motilal Oswal Securities Ltd. will host the call.

Dial in Details

India: +91 22 6280 1149 / +91 22 7115 8050 International Toll-Free USA UK Singapore Hong Kong : 1 866 746 2133 : 0 808 101 1573 : 800 101 2045 : 800 964 448 Express Join with Diamond Pass https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=23323 24&linkSecurityString=102d9acd80 You are requested to dial in 10 mins ahead of the scheduled start time. Purvi Shah / Isha Trivedi Investor Relations / Media Alkem Laboratories Ltd. Mobile: +91 84337 00890 / 98925 90003 Tel.: +91 22 3982 9999 Ext: 9447 E-mail: purvi.shah@alkem.com/ isha.trivedi@alkem.com Tushar Manudhane Institutional Research Analyst - Healthcare Motilal Oswal Securities Ltd. Tel.: +91 22 6129 1536 / +91 82911 38039

E-mail

Tushar.Manudhane@motilaloswal.com Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation: • General economic and business conditions in India and other key global markets in which we operate; • The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes; • Changes in the value of the Rupee and other currency changes; • Changes